RecruitMe Clinical Trial

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (CREAD2)
Study of New Drug in Patients with Cognitive Impairment or Mild Alzheimer's Disease
Sponsor:F. Hoffmann- La Roche Ltd.
Enrolling:Male and Female Patients
Age Range:Between 50 and 85 years old
IRB Number:AAAR6021
U.S. Government ID:NCT03114657
Contact: Katrina Cuasay: 212- 305- 2077 / kc2305@cumc.columbia.edu
Additional Study Information:

You have been selected as a possible participant in this study because you have memory or thinking problems (cognitive impairment) or mild Alzheimer's disease. Alzheimer's disease is a slow progressive disease of the brain that affects memory and brain function. Currently available medications for Alzheimer's disease provide limited symptomatic benefit and do not significantly change the course of the illness. This study may provide further understanding of the disease and potential benefits of treatment with crenezumab for patients with Alzheimer's disease. If it works, crenezumab may slow down how fast your disease progresses. It is not expected to improve your memory over current levels. You may not get any benefit from being in the study.

This study is closed
Investigator
Lawrence Honig, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Katrina Cuasay
Email: kc2305@cumc.columbia.edu
Phone: 212- 305- 2077